![Inside Scailyte – Episode 3: Peter Nestorov](https://scailyte.com/wp-content/uploads/2024/01/3rd-Video-Interview-Peter-Nestorov-1024x576.png)
Inside Scailyte – Episode 3: Meet Peter Nestorov
Inside Scailyte – Episode 3: Meet Peter Nestorov
Welcome to “Inside Scailyte” – Discovering Our Team!
At Scailyte, we’re driven by the incredible talents and dedication of our team members. They are the heartbeat of our innovation, propelling us toward success. That’s why we’re excited to present “Inside Scailyte,” our video interview series that uncovers the unique stories, expertise, and passions that define our exceptional team.
Episode 3: Meet Peter Nestorov
In this latest episode, we have the privilege to introduce you to Peter Nestorov, the Founder and CEO of Scailyte. Peter’s visionary leadership has been instrumental in shaping Scailyte into a pioneering force in precision medicine, combining the power of AI with single-cell analysis. Join us as Peter shares his inspiring journey, the pivotal role of Scailyte in the healthcare revolution, and his vision for the future of our industry.
Stay tuned for the premiere of “Inside Scailyte – Episode 3” and follow the upcoming episodes as we delve into the diverse talents and stories that make our team truly extraordinary.
We’re thrilled to embark on this journey with you! Don’t miss out—follow our page to catch all the episodes.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...